Back to search

Article

Brain, blood, and cerebrospinal fluid vascular biomarkers reflect distinct biology in Parkinson's disease

2026-07-10

Abstract excerpt

<title>Abstract</title> <p> Blood-brain barrier (BBB) biomarker pipelines in Parkinson's disease (PD) use brain transcriptomics, plasma proteomics, and cerebrospinal fluid (CSF) measures interchangeably, but whether they report on the same biology is untested. We pre-registered a PPMI study combining single-nucleus midbrain RNA-seq (18,120 vascular cells, three cohorts), whole-blood RNA-seq, a 20-protein BBB pan...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2a820572-279c-5f01-bcd8-2572f520a2ca
DOI
10.21203/rs.3.rs-10164864/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Brain, blood, and cerebrospinal fluid vascular biomarkers reflect distinct biology in Parkinson's diseaseDOI 10.21203/rs.3.rs-10164864/v1
Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and cerebrospinal fluidSemantic proximity
Identification of a novel proteomic Biomarker in Parkinson’s Disease: Discovery and Replication in Blood, brain and CSFSemantic proximity
Changes in the cerebrospinal fluid proteome precede and stratify the course of Parkinson’s DiseaseSemantic proximity
Plasma vs. serum: which is better for proteomic blood biomarker analysis? Evaluation of the novel NULISA platformSemantic proximity
Plasma acellular transcriptome contains Parkinson’s disease signatures that can inform clinical diagnosisSemantic proximity
Plasma Proteomics for Parkinson’s Disease: Diagnostic Classification, Severity Association, and Therapeutic HypothesesSemantic proximity
The Quest for a Universal Parkinson’s Transcriptomics Signature is Derailed by Inherent Variability between PatientsSemantic proximity
Parkinson’s disease causality and heterogeneity: a proteogenomic viewSemantic proximity
Blood transcriptomics reveals a Parkinson’s disease signature and heterogeneous prodromal molecular profiles in isolated RBDSemantic proximity
Transcriptomic signatures of brain regional vulnerability to Parkinson’s diseaseSemantic proximity
Leveraging blood RNA expression to understand Parkinson’s disease heterogeneity and progressionSemantic proximity
High-sensitivity plasma proteomics reveals disease-specific signatures and predictive biomarkers of Alzheimer’s disease phenotypes in a large mixed dementia cohortSemantic proximity
Select a neighboring publication to make it the new centre.